Understanding Continuous Levodopa-Carbidopa Intestinal Gel…

What is Continuous Levodopa-Carbidopa Intestinal Gel Therapy?

Continuous levodopa-carbidopa intestinal gel therapy (LCIG) is a treatment option designed to manage the symptoms of advanced Parkinson’s disease. This method involves delivering levodopa and carbidopa, two key components in managing Parkinson's, directly into the small intestine via an implanted pump system.

The primary advantage of LCIG over traditional oral medications is its ability to provide a more consistent and predictable delivery of these drugs, which can help reduce fluctuations in symptom control known as 'wearing off' or 'on-off' phenomena.

How Does LCIG Work?

In this therapy, levodopa-carbidopa gel is continuously infused into the small intestine through a tube that connects to an implanted pump. The gel bypasses the stomach and upper part of the gut where it can be broken down by digestive enzymes before reaching the brain.

Carbidopa, a peripheral decarboxylase inhibitor, prevents the breakdown of levodopa in the periphery, ensuring more of the drug reaches the central nervous system to cross the blood-brain barrier effectively.

live demo · related simulation● LIVE

Benefits and Considerations

The primary benefits of LCIG include improved motor function, reduced 'wearing off' periods, and a smoother transition between 'on' and 'off' states. Additionally, it can lead to better quality of life for patients by minimizing the side effects often associated with oral medications.

However, LCIG also comes with its own set of challenges, including potential complications such as infection at the site of implantation, pump malfunction, and gastrointestinal issues.

Patient Selection

LCIG is typically reserved for patients who have advanced Parkinson’s disease, characterized by significant motor fluctuations despite optimal oral medication management. It is often considered when other treatment options fail to provide adequate symptom control.

The decision to initiate LCIG therapy involves a thorough evaluation of the patient's condition, including their response to previous treatments and their overall health status.

Frequently asked questions

Who is a suitable candidate for LCIG?

LCIG is generally recommended for patients with advanced Parkinson’s disease who have significant motor fluctuations despite optimal oral medication management, and whose symptoms are not adequately controlled by other treatments.

What are the potential side effects of LCIG?

Potential side effects include gastrointestinal issues such as nausea, vomiting, and diarrhea. Other complications may involve pump-related infections or mechanical failures.

How is LCIG administered to patients?

LCIG is delivered through a tube that connects an implanted pump to the small intestine. The gel is continuously infused into the gut, bypassing the stomach and upper part of the digestive tract where levodopa can be broken down.

What are the main advantages of LCIG over oral medications?

LCIG provides a more consistent delivery of levodopa-carbidopa, which helps in reducing fluctuations in symptom control and improving overall motor function. It also minimizes side effects associated with oral medications.

Try it live

Everything above runs in your browser — open Continuous Levodopa-Carbidopa Intestinal Gel Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open Continuous Levodopa-Carbidopa Intestinal Gel Simulator simulation

Understanding Continuous Levodopa-Carbidopa Intestinal Gel Therapy in Parkinson’s Disease